Scholarlink

Background <p>Anthracyclines can induce endothelial and microvascular injury that precedes measurable myocardial dysfunction. However, reliable early markers of such injury are lacking. Nailfold capillaroscopy (NFC) is a noninvasive imaging technique that visualizes microcirculatory alterations. This pilot prospective study aimed to explore post-treatment NFC findings after anthracycline-based chemotherapy and their association with subclinical changes in left ventricular ejection fraction (LVEF) in patients with breast cancer.</p> Methods <p>Twenty-six patients with breast cancer scheduled for four cycles of neoadjuvant doxorubicin/cyclophosphamide (AC) were prospectively enrolled. All patients underwent baseline and post-chemotherapy echocardiography and post-treatment NFC assessment. Capillaroscopic abnormalities (tortuosity, crossing capillaries, extravasation, hemorrhage, dilated capillaries, giant capillaries, and neoangiogenesis) were recorded to generate a composite NFC score (0–7). Early cardiotoxicity was defined as ≥ 10% reduction in LVEF or LVEF &lt; 53%. Correlations between change in ejection fraction (ΔEF) and NFC score were analyzed using Spearman’s test. Exploratory ROC analysis was performed using any EF decline as a sensitive pilot endpoint, and an additional sensitivity analysis was performed using a more conservative threshold of ΔEF ≥ 3%.</p> Results <p>The mean age was 51.8 ± 11.2 years. Baseline and post-AC LVEF were 60.1 ± 2.2% and 58.4 ± 2.6%, respectively (ΔEF = -1.73 ± 2.15%). No clinical cardiotoxicity was observed. The mean composite NFC score was 3.15 ± 0.73. Higher NFC scores showed a negative correlation with ΔEF that did not reach statistical significance (Spearman ρ = -0.36, 95% CI: -0.67 to 0.00, <i>p</i> = 0.072). Exploratory ROC analysis using any EF decline as a sensitive pilot outcome yielded an AUC of 0.78 (95% CI: 0.57–0.95), with an optimal cutoff of NFC ≥ 4. In a sensitivity analysis using ΔEF ≥ 3%, the findings remained directionally consistent (AUC 0.79; optimal cutoff NFC ≥ 4).</p> Conclusions <p>Post-treatment NFC abnormalities were frequently observed after anthracycline-based chemotherapy and showed an exploratory association with modest subclinical declines in left ventricular ejection fraction. As a prospective pilot study integrating NFC with paired echocardiographic assessment in a homogeneous anthracycline-treated breast cancer cohort, this work provides early hypothesis-generating evidence for a potential microvascular imaging approach in cardio-oncology. Given the absence of baseline NFC assessment and the non-significant primary correlation, these findings should be interpreted cautiously rather than as evidence of anthracycline-induced microvascular injury. Larger longitudinal studies are warranted to clarify the potential role of NFC in cardio-oncology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nailfold capillaroscopy findings after anthracycline-based chemotherapy and their association with subclinical changes in left ventricular ejection fraction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月18日

查看全文
  • Murat Kiracı,
  • Gülşah Soytürk,
  • Fahriye Tuğba Köş,
  • Perihan Perkin,
  • Şükran Erten

摘要

Background

Anthracyclines can induce endothelial and microvascular injury that precedes measurable myocardial dysfunction. However, reliable early markers of such injury are lacking. Nailfold capillaroscopy (NFC) is a noninvasive imaging technique that visualizes microcirculatory alterations. This pilot prospective study aimed to explore post-treatment NFC findings after anthracycline-based chemotherapy and their association with subclinical changes in left ventricular ejection fraction (LVEF) in patients with breast cancer.

Methods

Twenty-six patients with breast cancer scheduled for four cycles of neoadjuvant doxorubicin/cyclophosphamide (AC) were prospectively enrolled. All patients underwent baseline and post-chemotherapy echocardiography and post-treatment NFC assessment. Capillaroscopic abnormalities (tortuosity, crossing capillaries, extravasation, hemorrhage, dilated capillaries, giant capillaries, and neoangiogenesis) were recorded to generate a composite NFC score (0–7). Early cardiotoxicity was defined as ≥ 10% reduction in LVEF or LVEF < 53%. Correlations between change in ejection fraction (ΔEF) and NFC score were analyzed using Spearman’s test. Exploratory ROC analysis was performed using any EF decline as a sensitive pilot endpoint, and an additional sensitivity analysis was performed using a more conservative threshold of ΔEF ≥ 3%.

Results

The mean age was 51.8 ± 11.2 years. Baseline and post-AC LVEF were 60.1 ± 2.2% and 58.4 ± 2.6%, respectively (ΔEF = -1.73 ± 2.15%). No clinical cardiotoxicity was observed. The mean composite NFC score was 3.15 ± 0.73. Higher NFC scores showed a negative correlation with ΔEF that did not reach statistical significance (Spearman ρ = -0.36, 95% CI: -0.67 to 0.00, p = 0.072). Exploratory ROC analysis using any EF decline as a sensitive pilot outcome yielded an AUC of 0.78 (95% CI: 0.57–0.95), with an optimal cutoff of NFC ≥ 4. In a sensitivity analysis using ΔEF ≥ 3%, the findings remained directionally consistent (AUC 0.79; optimal cutoff NFC ≥ 4).

Conclusions

Post-treatment NFC abnormalities were frequently observed after anthracycline-based chemotherapy and showed an exploratory association with modest subclinical declines in left ventricular ejection fraction. As a prospective pilot study integrating NFC with paired echocardiographic assessment in a homogeneous anthracycline-treated breast cancer cohort, this work provides early hypothesis-generating evidence for a potential microvascular imaging approach in cardio-oncology. Given the absence of baseline NFC assessment and the non-significant primary correlation, these findings should be interpreted cautiously rather than as evidence of anthracycline-induced microvascular injury. Larger longitudinal studies are warranted to clarify the potential role of NFC in cardio-oncology.